RapidInformationonOLMNo.docVIP

PAGE  PAGE 4 Rapid Information on Olmesartan and other ARBs No.210 2014/02/25 　　　　　　　　　　　　　　　　　 　　　　　　　　　Be the first to know! 　　　 　 　　 (Toru Komai, Ph.D.) 210-1: The fixed dose combination of OM, AM and HCTZ (40/10/25mg) resulted in reductions from baseline in mean 24h ambulatory SBP and DBP. Title：Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study　　　　　　　　　　　　　　　　　　　　　　　　　　　2-3 210-2：Olmesartan treatment was found to generate beneficial effects on metabolic syndrome parameters in hypertensive patients, but did not produce any significant increases in serum PPAR-γ transcription factor concentration. Title：Peroxisome Proliferator-activated Receptor Gamma Concentrations in Newly Diagnosed Patients with Hypertension and the Metabolic Effects of Olmesartan 3-4 Abbreviations: BP: blood pressure, SBP/DBP: systolic/ diastolic BP, RAS: renin–angiotensin system, Ang II: angiotensin II, ARB: angiotensin II receptor blocker, CCB: calcium channel blocker, ACE-I: angiotensin converting enzyme inhibitor, AML: amlodipine, HCTZ: hydrochlorothiazide, BMI: body mass index, 210-1: The fixed dose combination of OM, AM and HCTZ (40/10/25mg) resulted in reductions from baseline in mean 24h ambulatory SBP and DBP. BP goals are reached in only one-third of patients receiving monotherapy. As a result, in the majority of patients with hypertension, particularly those with stage 2 hypertension, combination therapy is required to achieve recommended BP goals. ARBs, HCTZ and CCBs differ in their mechanisms of action but studies have found that they may have complementary actions, which could explain why the triple combination is effective and has a lower incidence of adverse ef